Overview
Century Therapeutics reports Q3 net loss of $34.4 mln, compared to $31.2 mln last year
R&D expenses decreased to $22.5 mln in Q3, primarily due to reduced personnel costs
Outlook
Century plans to initiate IND-enabling studies for T1D program by end of 2025
Company expects to advance CNTY-308 into clinical studies in 2026
Century estimates cash runway into 4Q 2027
Result Drivers
COSTS DECLINE - R&D expenses lower primarily due to a reduction of personnel and manufacturing costs, while G&A expenses decrease due to a gain on lease modification
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$34.42 mln | ||
Q3 Basic EPS | -$0.40 | ||
Q3 Operating Expenses | $36.12 mln | ||
Q3 Operating Income | -$36.12 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Century Therapeutics Inc is $6.00, about 90.6% above its November 12 closing price of $0.56
Press Release: ID:nGNX9gH2x6
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)